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Aquatic versus Mammalian Toxicology:
Applications of the Comparative Approach
by Anthony M. Guarino*
The large body of literature and techniques generated by mammalian toxicity studies provides a con-
ceptual and technical framework within which the absorption, fate, and disposition of xenobiotics in
aquatic organisms can be studied. This review emphasizes the similarities and differences between mam-
malian and aquatic systems, e.g., lung vs. gill as site ofabsorption and toxicity. These must be taken into
consideration when designingaquatictoxicity studies. Studies ofphenol red indogfish sharkas anexample
show physiologic-based pharmacokinetic modeling to be a useful tool for investigating and eventually
predicting species differences in xenobiotic disposition and drug differences within the same species. This
discussion demonstrates that both laboratory and modeling procedures are now available to carry out
sophisticated studies of xenobiotic fate and disposition in fish. Such studies are needed to pinpoint sites
and mechanisms of pollutant toxicity in aquatic organisms.
Introduction
Reviewed here are the basic tenets of a pharmaco-
kinetic assessment of xenobiotic toxicity. In so doing I
hope to stress the interactions between body compart-
ments and to provide examples that will assist the read-
ers to integrate the more specific discussions which fol-
low into an overall picture of the current state of our
knowledge of pollutant action in aquatic organisms. In
particular, the impact ofspecialized systems will be ad-
dressed, e.g., gills vs. lungs, on the fate, distribution,
andtoxicity ofxenobiotics. Such considerations are very
important if we are to avoid such fundamental flaws in
experimental design asimproper exposure route or con-
ditions. Secondly, it will be shown that aquatic toxicol-
ogy does not exist in a vacuum. Available for use are a
wealth ofexperience and numerous sophisticated mod-
eling devices developed in mammalian toxicological re-
search, particularly in pharmacokinetic modeling. We
need not rediscover the wheel. Finally, how some of
the specializations ofaquatic organisms may be used to
advantage in assessing mechanisms of pollutant action
in aquatic organisms and in all organisms will be de-
scribed.
The Comparative Approach
Toxicology is the study ofthe harmful actions ofsub-
stances on biologic tissues. Mammalian or warm-
blooded terrestrial species are more commonly studied
when one is concerned primarily with predicting health
effects inhumans. Aquatic and wild lifespecies are stud-
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ied when there is focus on potential environmental ef-
fects. In contrast, the comparative approach moves
back and forth among species, but invariably is con-
cerned with common fundamental biologic processes.
The basic tools and kinds of end points sought are
similar in aquatic and classical toxicology. Aquatic tox-
icology is concerned with qualitative and quantitative
aspects of the undesirable effects of xenobiotics on
aquatic organisms. These undesirable effects range
from the sublethal to the lethal and include changes in
behavior, growth, development, reproduction, and
pharmacologic responses, as well as underlying cellular
effects at the histopathologic, biochemical, and physi-
ologic levels. The field is also concerned with the con-
centrations of xenobiotics expected to occur in water,
sediment, and food. This encompasses the transport,
distribution, transformation, and ultimate fate ofchem-
icals in our aquatic environment (1).
I see more similarities than differences between clas-
sical mammalian toxicology and aquatic toxicology.
These similarities show up in a number of areas (Fig.
1). Those familiar with the mammalian field will recog-
nize mostofthismaterial. Thisfigure showsthestarting
point formammalian mechanistic studies about20years
ago. This is also where we are now in the aquatic area,
since we have just begun or have yet to begin work on
mechanisms in many ofthese areas.
Overview of Absorption, Fate, and
Disposition of a Xenobiotic
Before exerting any pharmacologic or toxicologic ef-
fect, a xenobiotic must arrive at its site of action at a
suitable concentration andremainthere foranadequateA. M. GUARINO
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FIGURE 1. Overview of absorption fate and disposition ofxenobiotics in mammals and fish.
length of time. Whether or not sensitive sites will be
exposed toxenobiotic concentrationssufficienttoimpair
function is determined by many processes, including
absorption, biodistribution, excretion, metabolism, in-
teractions with pharmacological receptors, and binding
to macromolecules. The rate of onset of a particular
action following xenobiotic treatment is influenced by
the routes ofexposure, mode ofadministration, and the
ratesofpenetrationthroughasuccessionofmembranes.
The duration of xenobiotic action is altered depending
on rates of accumulation into tissues, metabolism, and
excretion. Initially, species differences in xenobiotic ac-
tivity were explained by qualitative and quantitative
differences in the biotransformation of the compound.
More recently, it has become apparent that there are
also differences between species in the absorption, dis-
tribution, and excretion of chemicals (2).
The right side of Figure 1 depicts the six kinds of
effects which can be demonstrated after exposure ofan
animal to a bioactive substance. All six kinds ofeffects
have been invariably demonstrated first in terrestrial
animals and laterinaquatic species. Notshown are local
effects which tend to be due to direct actions on the
surfaces exposed to substances in the ambient media,
e.g., fishskinandgill lesions fromacid wastesand mam-
malian respiratory tract changes from exposure to gas-
eous toxicants. The "local" mechanisms, while certainly
important, tend to be less interesting scientifically than
systemic toxic effects.
In summary, Figure 1 shows the specific processes
to be considered before undertaking studies of toxico-
logic mechanisms involving aquatic species. Many of
these will be addressed in greater detail in these pro-
ceedings. Each process will be discussed here from
three general points of view: (1) What do we know
about its operation in aquatic species? (2) What have
we learned from mammalian studies? (3) Can any of
this knowledge be applied to aquatic species? Answers
to these three questions clearly underlie the use ofthe
comparative approach.
Exposure and Absorption
Inmostmammalianlaboratorystudies, xenobioticex-
posure is by oral, intraperitoneal, or pulmonary routes.
In the majority offish studies, exposure is by addition
of the test substance to the water. In the latter case,
it may be difficult to dissect out the relative importance
of oral, skin, and gill uptake. Thus, the block labeled
"exposure" in Figure 1 requires some comparisons to
be made between the two fields of toxicology, mam-
malian and aquatic.
The major fraction of absorbed xenobiotics comes
from the ambient media from which terrestrial and
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aquatic species obtain oxygen (air or water) and food.
For example, during exchange of oxygen for carbon
dioxide, chemicals in the surrounding air or water are
brought to the surfaces ofeither ofthe two highly vas-
cular organs, the lungs and the gills. At the air-lung
or water-gill interfaces, physiocochemical factors de-
termine the degree ofxenobiotic absorption. These fac-
tors are the same ones that would determine rates of
absorption by any route.
The physiocochemical factors that favor absorption of
chemicals across mammalian membranes are well
known. Most foreign compounds cross biologic mem-
branes bypassive diffusion andusually onlylipid soluble
and uncharged xenobiotics of low molecular weight
readily diffuse through membranes (3). The degree of
ionization is controlled by the pKa ofthe compound and
the pH ofthe body compartments in which the chemical
is distributed. Many mammals have a gastric pH of
about 1, an intestinal lumen pH of 5.3 to 7.8, and a
plasma pH of 7.4. Thus, given the pKa of a compound,
one can predict the site and degree of absorption. For
example, a xenobiotic which is a weak acid will be
largely in the un-ionized form in the stomach and there-
fore readily diffuse across the stomach wall. Similarly,
foreign compounds which areweakbases, and therefore
partially un-ionized atthe pH oftheintestinal tract, will
readily pass into the bloodstream from this site. In gen-
eral, highly ionized molecules will not be absorbed from
the gastrointestinal tract or gill unless a specific mech-
anism for transport exists. We know the stomach and
intestinal tract pH for only a few aquatic species; thus,
we are handicapped in predicting the degree of xeno-
biotic absorption.
It is often assumed that pharmacokinetic phenomena
established inmammalsalsooperateinfish. Werecently
had occasion to test this assumption in two species,
channel catfish (Ictalurus punctatus) and striped bass
(Morone saxatilis), under active oral treatment with
oxytetracycline (OTC) (4). Very high gastrointestinal
tract levels of the drug were found, but the liver had
very low levels, and levels in muscle were negligible.
In a follow-up study with 3H-tetracycline, the bioavail-
ability following oral administration was shown to be
less than 5% (4). This was determined in the traditional
way, i.e., by comparing the oral and intravenous area
under the curve of drug concentration vs. time. Bioa-
vailability was not substantially influenced by the pres-
ence of food.
Thus, an important gap in our comparative pharma-
cology hasbeen discovered. There are no in-depth stud-
ies in any aquatic species that establish the optimal
physiocochemical properties favoring gastrointestinal
tract absorption. This is surprising, since many excel-
lent nutritional studies have been conducted in aquatic
species, and the techniques utilized for studying nu-
trient absorption generally could be applied to xeno-
biotics. One practical reason we need this information
is that aquaculture is growing rapidly in the U.S. and,
as seen in the intense farming ofother animals, aquatic
species succumbtobacterialdiseasesthatcanbetreated
with antibiotics. But which ones will work? Unfortu-
nately, treatment has been hit-or-miss so far.
The above cited study is one of the first true bioa-
vailability studies for a drugin fish. Recently, Varanasi
and co-workers examined the bioavailability ofthe car-
cinogen benzo(a)pyrene, demonstrating its availability
in contaminated sediments (5). Clearly, we need more
fish bioavailability studies ifwe are to accurately assess
both the therapeutic and the environmental impacts of
drugs and other xenobiotics.
Having discussed absorption that occurs while in-
gesting food or while extracting oxygen from air or
water, let us note a third exposure route-the skin.
Herethe barriers varyin structural complexityranging
from direct integument exposure to the imposition of
extra barriers such as fur and scales or horns and
hooves. Again, data quantifying dermal absorption of
chemical entities in mammals are far more extensive
than for aquatic species. While technically challenging,
it is criticalthat studies which separately quantifyrates
ofxeobiotic absorption from the waterviathe gills, gut,
and skin be performed.
Biodistribution
Exposure conditions and absorption rates determine
how xenobiotics get into the body. We must also con-
siderwhereandhowchemicalsaredistributedoncethey
have entered the bloodstream, i.e., biodistribution.
Some factors determiningxenobiotic biodistribution are
blood flow, plasma binding and transport, blood-organ
barriers, tissue binding, and tissue uptake, both diffu-
sion rate-limited and perfusion rate-limited.
Obviously, the rate at which blood flows through an
organ is a prime determinant ofhow much ofa chemical
in the blood will reach the tissue. One major determi-
nant oftissue perfusion is heartrate. One ofthe highest
rates among mammals occurs in the mouse (600 beats/
min). Fish such as eel and dogfish sharks have rates
only one-tenth those seen in mice. It is important to
note that physiologic-based pharmacokinetic modeling
techniques can compensate for these wide differences
and therefore provide a powerful tool for comparative
studies.
Binding to plasmaproteins is a second important pro-
cess that determines the biodistribution of chemicals.
In one sector, industrial drugdevelopment, plasmapro-
tein binding is routinely measured for new drugs. Only
rarely does one see such studies where drugs or indus-
trial contaminants are tested in fish. Since the compo-
nent proteins in aquatic and mammalian plasma can be
quite different, it is likely that the degree of protein
binding may also be very different. Binding can alter
the efficiency oftissue extraction ofthe chemical as the
blood perfuses a given organ because ofcompetition for
xenobiotics between plasma proteins and tissue com-
ponents. Compounds highly bound to plasma proteins
relative to tissue sites will show higher retention in
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plasma. Substances with highaffinities forcertain tissue
components, e.g., heavy metals for sulfhydryl proteins
such as metallothionein (6) and DDT for body fat, will
show high tissue/plasma ratios. An overview ofspecies
differences in plasma protein levels and protein frac-
tions (7) appears in Table 1.
Two points are particularly noteworthy: (1) the range
oftotal protein levels is 1.7 to 11.0 g/100 mL; and (2) a
number of protein fractions are undetectable (0.0%) in
several species. Obviously these two factors will alter
the qualitative and quantitative aspects of xenobiotic
binding to plasma of different species.
Even though a blood-borne toxicant is presented to
a certain organ, a blood-organ barrier may prevent its
entry, thus protecting that organ from adverse effects.
Perhaps the most famous of these is the blood-brain
barrier. Some feel this is more a functional character-
istic than a specific anatomic structure. Certainly, some
exclusion of blood-borne chemicals has been shown by
the brains of nearly every animal tested, even in those
lower species without the complex mammalian type of
blood-brain barrier (8). However, because oftheir sim-
pler barriers, fish would be expected to offer less re-
sistance to penetration oflipid soluble CNS intoxicants
than most mammalian species. As a class, aquatic spe-
cies do seem to be more sensitive than mammals to such
CNS active chemicals.
The last factor determining biodistribution is tissue
uptake. The rate ofxenobiotic entry into tissue may be
limited by diffusion barriers or by vascular perfusion
rates. Uptake will be diffusion rate-limited if a sub-
stance's movement across membranesis slow. As a gen-
eral rule, highly water-soluble compounds tend to be
diffusion rate-limited. On the other hand, molecules are
perfusion rate-limited if the rate of diffusion across
membranes is rapid. Then tissue uptake is limited by
the rate atwhichthe chemicalisdelivered tothetissues,
i.e., by the vascular perfusion rate.
Excretion
Toxicity of a given agent is not determined solely by
its ability toreach a sensitive targetsite. The compound
must also reach a sufficient concentration at the site to
exert an effect. Therefore, the efficacy ofexcretion may
profoundly influence the extent to which toxicity is ex-
pressed. Aquatic and terrestrial species utilize three
primary routes of excretion (Table 2). In both classes
of animals, two are similar, the urinary and biliary
routes. Fish also excrete some substances via the gills,
whereas mammals utilize the lungs as a way ofridding
their body ofcertain chemicals. Other more specialized
routes are also listed in Table 2.
Substances excreted in the urine ofmammals are also
Table 1. Species differences in plasma levels of selected proteins.
Protein in fractions, %
Total protein, Albumin and
Species gIlOO mL prealbuminb a 1-globulin a 2-globulin a globulin y globulin
Mammals
Human 7.4 56.5 2.4 12.1 10.6 18.4
Monkey 8.8 56.0 2.7 6.6 29.0 5.6
Seal 4.9 53.3 3.6 20.8 15.8 6.5
Swine 11.0 46.5 0.0 20.1 16.6 16.8
Goat 6.3 63.8 8.1 0.0 15.6 12.5
Horse 6.9 41.3 0.0 14.7 12.7 31.3
Lamb 7.1 50.9 0.0 18.2 7.3 23.6
Cattle 7.8 41.8 0.0 14.4 12.9 30.9
Hamster 4.9 58.4 15.0 2.7 6.2 17.7
Guinea pig 3.6 59.1 24.0 4.2 2.8 9.9
Rat 6.7 47.1 27.0 0.0 18.4 7.5
Rabbit 5.7 67.9 2.2 12.4 9.6 7.9
Dog 9.0 29.2 4.1 19.9 13.3 33.5
Mouse 6.2 52.7 20.2 0.0 20.9 6.2
Cat 6.8 25.4 2.6 21.2 10.9 39.9
Aquatic
Lobster 2.0 79.8 0.0 17.4 0.0 2.8
Dogfish 2.8 41.8 0.0 53.5 0.0 4.7
Amphibian
Turtle 4.1 10.5 0.0 26.4 27.2 35.9
Frog 2.7 71.2 0.0 17.3 11.5 0.0
Avian
Turkey 4.6 46.2 0.0 12.5 14.4 26.9
Duck 3.5 51.8 3.8 5.1 15.2 24.1
Pigeon 2.3 36.8 0.0 13.1 35.8 14.3
Goose 1.7 58.6 0.0 41.4 0.0 0.0
Chicken 3.5 57.1 0.0 15.6 27.3 0.0
aRevised from Guarino et al. (1). Standard total protein assay and plasma paper electrophoretic methods were used.
bMethod used did not differentiate between pre-albumin and albumin and therefore is reported as composite.
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Table 2. Major excretory routes.
Aquatic species Terresterial species
Urine Urine
Bile Bile
Gills Lungs
Others Others
Eggs Milk
Skin/mucus Sweat
excreted in fish urine via roughly similar mechanisms.
In fact, the development of our current understanding
ofrenal function demonstrates that the "success ofthe
comparative approach ... is dependent upon anatomical
differences between species" (8). When researchers
were trying to elucidate the roles ofthe tubule and the
glomerulus in urine formation, they realized that the
goose-fish (Lophius americanus) was aglomerular and
the hagfish (Myxine glutinosa) was atubular. Work in
these two species, especially the goosefish, greatly clar-
ified the functional role ofthe different anatomic struc-
tures ofthe kidney. It also demonstrated that nephron
segment function is highly conserved, i.e., morpholog-
ically similar segments do similarjobs in fish and mam-
mals.
Biliary excretion has not been as extensively studied
in fish as in mammals. Dr. John Lech and I (9) recently
reviewed this topic and noted that each of us had in-
dependently concluded morethan adozen years agothat
mammals and fish were concentrating xenobiotics in the
bile and that this process could be exploited for envi-
ronmental and regulatory monitoring purposes. We re-
ported (9) that for 44 drugs and other xenobiotics in
several species of fish, concentrations of chemicals in
bile most often were considerably higher than those in
plasma orambient water, with38of44compounds (86%)
yielding bile/plasma or bile/water ratios greater than
unity. Indeed, forabouthalfofthese compounds ortheir
metabolites, concentrationratios exceeded ten. Thetre-
mendous analytic advantage of sampling the biliary
compartment offish is obvious. In mammals, a species-
dependent molecular weight threshold favoring biliary
transport has been proposed (10), with a typical range
of 275 to 375 daltons reported for the rat. Our dogfish
shark data indicate a higher threshold, in the 400 to 500
dalton range. Further work on other aquatic species
needs to be done.
Metabolism and Other Reactions with
Biomolecules
The second major general mechanism preventing ac-
cumulation oftoxic agents within the cell is conversion
to less toxic metabolites, i.e., deactivation or, as we
used to say, detoxification. However, some chemicals
are metabolically activated by inducible enzymes to
form reactive metabolites.
Metabolites in turn are further biodistributed, and
some react with low molecular weight compounds, such
asglucuronic acid, oraminoacids, such astaurine, yield-
ingless active but more polar conjugates. Unstable me-
tabolites can go on to react with macromolecules. Ifnot
degraded or repaired (Fig. 1) the adducts can produce
a host ofeffects ranging from alterations in the immune
system to reproductive, carcinogenic, or mutagenic re-
sponses. Clearly this is a highly complex and important
area. Several of the subsequent papers in this volume
deal with these questions, both for organic pollutants
and metals.
The other side of the coin with respect to reactions
with macromolecular species within the cell is that each
of the six classes oftoxicity shown on the right side of
Figure 1 reflects interactions between xenobiotics (or
metabolites) and biologically important macromolecules
ranging from nucleic acids and receptors to enzymes
and transport proteins. These interactions and their
toxicologic manifestations are the focus of many of the
other reviews covered in this volume.
Comparative Aspects of One
Xenobiotic in One Fish Species
For the rest of this paper I will use data on one xe-
nobiotic, phenol red, to show the similarities between
mammals and fish in their handling of foreign com-
pounds. This work, recently reviewed (11), will be out-
lined here, becauseit clearlydemonstratesthe presence
of physiologic/pharmacologic mechanisms in fish which
are remarkably similar to those in mammals. Further-
more, these data show that techniques currently avail-
able for marine fish permit the kind of sophisticated
pharmacokinetic analysis necessaryto focus in onmech-
anisms of pollutant action.
The studies were conducted in the dogfish shark
(Squalus acanthias), but the procedures developed and
employed can be readily adapted to other fish. Our
choice ofthe dogfish shark was based on the early stud-
ies ofRall and Zubrod (12). In 1962, they demonstrated
that the disposition (distribution of drug between red
blood cell, brain, and muscle) of the antimalarial drug
quinine was similar in dogfish sharks to that reported
in terrestrial mammals. Despite its promise, use ofthe
shark as a model for drug disposition studies required
the development of practical techniques for sampling
important physiologic compartments, such as the uri-
nary and biliary systems, and validation of pharmaco-
kinetic parameters. Phenolred, adrugwithwell-known
affinities for the renal compartment, was selected for
evaluating the shark model and the efficacy of these
new techniques.
The methods for collecting urine and bile (via biliary
fistula) have been described (11). The shark proved
hardy enough to survive these surgical manipulations
and could be routinely maintained for at least one week
following the facile intravenous (IV) injection of drug.
All of the following tissues and fluids were sampled
routinely: blood, urine, kidney, muscle, CSF, brain,
liver, and bile.
To determine the disposition of phenol red in the
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shark, we studied the transport properties of phenol
red in both the renal and hepatic systems. To obviate
absorption problems, the drugwas injected intothe tail
vein. Phenol red was rapidly and biphasically cleared
fromtheplasmacompartmentwithaninitialto.5ofabout
1 hr and a second phase to.5 of8 hr. As early as 10 min
after injection, phenol red was detectable in kidney tis-
sue. Hepatic levelstooklongertopeak (about2hr)than
kidney levels and decayed with a half-time of about 10
hr. The glucuronide metabolite was not detected in
plasma, kidney, or liver. Both phenol red and its glu-
curonide were found in urine within 30 min; they in-
creased in concentration for the first 2 hr and then de-
clined. The amount ofconjugated drug appearing in the
bile ranged from 15to30% ofthe total materialpresent.
Although obviously an important excretoryroute, renal
tissue never contained more than 6% of the adminis-
tered dose, and the renal percentage declined rapidly
after 1 hr. After 10 min the hepatic compartment con-
tained about 18% ofthe administered compound; a peak
occurred at 2 hr, and this compartment continued to
contain large amounts ofphenol red forup to 12 hr. The
total amounts ofphenol red handled by the urinary and
biliary systems over 48 hr were about 40% and 50%,
respectively. In these compartments, most of the ma-
terial was parent compound rather than metabolite.
To estimate the impact of enterohepatic circulation,
biliary and urinary excretion of phenol red in normal
and in biliary fistulized sharks were compared. The in-
tact animal normally excreted 49% ofthe administered
dose in 48 hr into gall bladder bile. Of this, 20% was
excreted as the glucuronide conjugate. In 48 hr, 41% of
the administered dose appeared in the urinary com-
partment ofintact animals. When bile was collected via
fistula, essentially the same fraction (47%), of the ad-
ministered dose appeared in the bile; however, com-
pared with the intact animal, about twice as much was
the glucuronide conjugate (44% vs. 20%). These data
suggest that the liver synthesizes the glucuronide and
readily excretes it into the bile. In the animals with
fistulae, alarge proportion ofthe administered dosewas
diverted, preventing the reabsorption ofthe glucuron-
ide (presumably after hydrolysis) via the gastrointes-
Table 3. Effects of different doses of phenol red on its
distribution in the dogfish shark.a
Tissue or fluid
(form ofphenol Dose, ,ug/g or mL
red) 10 mg/kg 100 mg/kg Increase
Plasma (free) 16 204 12.8
Kidney (free) 83 948 11.4
Liver (free) 38 155 4.1
Urine (free) 711 1777 2.5
Urine (glucuron- 63 148 2.3
ide)
Bile (free) 262 936 3.6
Bile (glucuronide) 120 241 2.0
aAnimals were treated intravenously with 10 or 100 mg/kg phenol
red. Values are means of five or six animals per dose 4 hr after
treatment.
tinal tract. The urinary excretion in surgically treated
animals confirmed this latter point, since animals with
fistulae excreted only 23% ofthe dose in urine in 48 hr
compared with 41% in intact animals.
Consistent with the effective biliary and urinary ex-
cretion, phenol red was actively transported from
plasma into renal and hepatic compartments. For ex-
ample, 6 hr after dosing, the kidney/plasma value for
free phenol red was 6.4 and the urine/plasma ratio was
30.4. Similarly, the liver/plasma value was 3.9 while the
bile/plasmaratio was64.3. Whenthedosewasincreased
from 10 to 100 mg/kg, the level of phenol red in the
plasma increased roughly proportionally, i.e., 12.8-fold
(Table 3). Renal tissue content also increased approxi-
mately 10-fold. On the other hand, liver, urine, and
biliary compartments increased far less than plasma,
i.e., saturated.
It was also possible to characterize the transport pro-
cess involved using inhibitors of specific pathways. In
this case, phenol red was knownto be excreted inmam-
mals via the organic anion transport system. Probe-
necid, the classical inhibitor for this system, signifi-
cantlyreduced renaltissue, urine, and bile levels offree
phenol red and its glucuronide (11). The effect was
FIGURE 2. Bodycompartments important inphenolred distribution
studies in dogfish shark. Qi is the plasma flow rate in mL/min
through kidney (K), liver (L), and muscle (M); ri is the total rate
ofphenol red andglucuronide transported interms ofp.g/minfrom
the liver (i = 0) and bile duct (i = 1,2) compartments; and T is
the nominal residence time for each bile duct compartment in
minutes. From Bungay et al. (13).
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somewhat more dramatic on the uptake of the glucu-
ronide, suggesting that probenecid may be inhibiting
both the transport and metabolism ofphenol red. Pro-
benecid pretreatment in vivo also caused a slight but
significant decrease in the amount ofphenol red binding
in plasma.
Thus, study ofthe model compound, phenol red, en-
abled us to determine that the following features tra-
ditionally studied in mammalian systems could also be
readily studied in fish: overall disposition and metabo-
lism, effects ofbiliary fistula, effects ofactive transport
in vivo, saturability of urinary and biliary excretion
mechanism, inhibition ofrenal and hepatic transport by
probenecid, and the presence ofsignificant plasma pro-
tein binding. Furthermore, the data were qualitatively
similar to that obtained in mammals.
Having developed these experimental techniques for
the dogfish shark, we next established the applicability
of pharmacokinetic scaling processes in the direction
oppositethatusuallytaken; pharmacokinetic models de-
veloped for mouse and extrapolated to man were used
to go the other way, i.e., from mouse to fish (13). The
general purpose ofdeveloping pharmacokinetic models
is to describe the time course of xenobiotic disposition
processes in the body. Thus, if it is possible to extrap-
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In atypical physiological pharmacokinetic model (Fig.
2), physiological parameters such as the blood flow rate
, I 1 _ -- K and blood volume of organs and tissues are used along
ljO t] _. I_ _ ~~-_ withbiochemical andphysiocochemicalparameters such
T 1 I --_ L 4 ~_ as plasma protein binding, lipid solubility, and tissue/
plasma concentration ratios (partition coefficients). The
resulting model (Fig. 2) is composed of a series of com-
partments representing organs or tissues within which
the xenobiotic concentrations are assumed to be uni-
1 ~~~ p ~~form. One writes differential mass balance equations
for each of these compartments to describe the inflow,
outflow, accumulation, or disappearance of the xeno-
biotic. A key feature ofthe physiologic-based approach
to pharmacokinetic modeling is that it can provide the
\means for predicting xenobiotic concentrations in tis-
\M sues that may be the target of certain toxic actions.
Furthermore, it is adaptable to changing physiologic
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Model predictions vs. experimental results for time values in mL/min) are needed.
of tissue and plasma concentrations of phenol red. Lines Predictions obtained from the shark model are shown
del predictions; symbols are experimental data for IV in- in Figure 3. Also shown in Figure 3 are the actual data
of10mg/kginto caudal vein ofdogfish sharks. Eachsymbol points we collected for phenol red organ distribution
ents average of 5-8 female sharks/time point with SD in- (13). The urinary and biliary data are shown in Figure by vertical bars. Limit of sensitivity of assay was 25, 15, 43 Cerly the collected dataaremownmreicton
ug/g or mL for (A) kidney (K); (E) liver (L); and (0) plasma 4. Clearly, the collected data and the model predictions
spectively. From Bungay et al. (13). agree well (13).
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In conclusion, even a practical regulatory agency,
such as FDA, has acknowledged the need for a com-
parative species approach. Appearing in a 1983 Federal
Register notice (14) was the following statement: "The
ability to extrapolate reliably between species will de-
pend on the amount of information available to the
agency regarding the species involved, the nature of
the disease or infection, the metabolism of the species
involved, etc. The regulation contemplates a great deal
of extrapolation between species." The dogfish shark
has yielded excellent data consistent with similar stud-
ies on terrestrial mammals. The major transport and
metabolic parameters in this fish were shown to be sim-
ilar to those found in mammals. There is no reason why
the techniques now established for this shark could not
beapplied withminormodifications toanumberofother
species and xenobiotics of interest to the aquatic toxi-
cologist. Indeed, such studies ofxenobiotic fate and dis-
tribution are critical to pinpoint sites and mechanisms
of pollutant toxicity in aquatic organisms.
The author thanks Ms. Patsy Purvis and Debbie Garner for the
skillful typing ofthe manuscript and Mr. Robert J. Martin.
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